与小分子抑制剂PJ34和XAV939结合的人端锚聚合酶1的结构
Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939.
作者信息
Kirby Christina A, Cheung Atwood, Fazal Aleem, Shultz Michael D, Stams Travis
机构信息
Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA.
出版信息
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Feb 1;68(Pt 2):115-8. doi: 10.1107/S1744309111051219. Epub 2012 Jan 21.
Abstract
The crystal structures of tankyrase 1 (TNKS1) in complex with two small-molecule inhibitors, PJ34 and XAV939, both at 2.0 Å resolution, are reported. The structure of TNKS1 in complex with PJ34 reveals two molecules of PJ34 bound in the NAD(+) donor pocket. One molecule is in the nicotinamide portion of the pocket, as previously observed in other PARP structures, while the second molecule is bound in the adenosine portion of the pocket. Additionally, unlike the unliganded crystallization system, the TNKS1-PJ34 crystallization system has the NAD(+) donor site accessible to bulk solvent in the crystal, which allows displacement soaking. The TNKS1-PJ34 crystallization system was used to determine the structure of TNKS1 in complex with XAV939. These structures provide a basis for the start of a structure-based drug-design campaign for TNKS1.
摘要
报道了端锚聚合酶1（TNKS1）与两种小分子抑制剂PJ34和XAV939复合物的晶体结构，分辨率均为2.0 Å。TNKS1与PJ34复合物的结构显示，两个PJ34分子结合在NAD(+)供体口袋中。一个分子位于口袋的烟酰胺部分，如先前在其他PARP结构中观察到的那样，而第二个分子则结合在口袋的腺苷部分。此外，与未结合配体的结晶系统不同，TNKS1-PJ34结晶系统在晶体中使NAD(+)供体位点可被大量溶剂接触，这允许进行置换浸泡。TNKS1-PJ34结晶系统用于确定TNKS1与XAV939复合物的结构。这些结构为开展基于结构的TNKS1药物设计活动奠定了基础。
相似文献
1
Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939.与小分子抑制剂PJ34和XAV939结合的人端锚聚合酶1的结构
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Feb 1;68(Pt 2):115-8. doi: 10.1107/S1744309111051219. Epub 2012 Jan 21.
2
The binding mechanism of a novel nicotinamide isostere inhibiting with TNKSs: a molecular dynamic simulation and binding free energy calculation.一种新型烟酰胺类似物对TNKSs的抑制作用的结合机制：分子动力学模拟和结合自由能计算
J Biomol Struct Dyn. 2016;34(3):517-28. doi: 10.1080/07391102.2015.1043580. Epub 2015 Dec 9.
3
Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor.Tankyrase-2 与强效 Wnt 信号抑制剂相互作用的结构基础。
J Med Chem. 2010 Jul 22;53(14):5352-5. doi: 10.1021/jm100249w.
4
Novel binding mode of a potent and selective tankyrase inhibitor.一种有效且选择性的 Tankyrase 抑制剂的新型结合模式。
PLoS One. 2012;7(3):e33740. doi: 10.1371/journal.pone.0033740. Epub 2012 Mar 16.
5
Structure-based design, synthesis and evaluation in vitro of arylnaphthyridinones, arylpyridopyrimidinones and their tetrahydro derivatives as inhibitors of the tankyrases.基于结构的芳基萘啶酮、芳基吡啶并嘧啶酮及其四氢衍生物作为端锚聚合酶抑制剂的设计、合成及体外评价
Bioorg Med Chem. 2015 Jul 1;23(13):3013-32. doi: 10.1016/j.bmc.2015.05.005. Epub 2015 May 13.
6
Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.深入了解聚（ADP-核糖）聚合酶（PARP）抑制剂与人端粒酶2催化结构域的结合情况。
Acta Crystallogr D Biol Crystallogr. 2014 Oct;70(Pt 10):2740-53. doi: 10.1107/S1399004714017660. Epub 2014 Sep 27.
7
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.聚（ADP-核糖）聚合酶（PARP）和端锚聚合酶抑制剂的效力与混杂性的结构基础
J Med Chem. 2017 Feb 23;60(4):1262-1271. doi: 10.1021/acs.jmedchem.6b00990. Epub 2016 Dec 21.
8
XAV939 promotes apoptosis in a neuroblastoma cell line via telomere shortening.XAV939通过端粒缩短促进神经母细胞瘤细胞系的凋亡。
Oncol Rep. 2014 Nov;32(5):1999-2006. doi: 10.3892/or.2014.3460. Epub 2014 Sep 2.
9
Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket.发现一类新型的 Tankyrase 抑制剂，它们可以同时结合烟酰胺口袋和诱导口袋。
J Med Chem. 2013 Feb 14;56(3):1341-5. doi: 10.1021/jm301607v. Epub 2013 Jan 23.
10
Tankyrase Sterile α Motif Domain Polymerization Is Required for Its Role in Wnt Signaling.端锚聚合酶无菌α基序结构域的聚合作用对其在Wnt信号传导中的作用至关重要。
Structure. 2016 Sep 6;24(9):1573-81. doi: 10.1016/j.str.2016.06.022. Epub 2016 Aug 4.
引用本文的文献
1
The post-translational modification of NuMA in cancer cells is a new target for cancer eradication.癌细胞中核有丝分裂器蛋白（NuMA）的翻译后修饰是根除癌症的新靶点。
Cell Death Dis. 2025 Jul 18;16(1):536. doi: 10.1038/s41419-025-07868-7.
2
Tankyrase-1 regulates RBP-mediated mRNA turnover to promote muscle fiber formation.端锚聚合酶-1调节RBP介导的mRNA周转以促进肌纤维形成。
Nucleic Acids Res. 2024 Apr 24;52(7):4002-4020. doi: 10.1093/nar/gkae059.
3
Combinatorial Virtual Screening Revealed a Novel Scaffold for TNKS Inhibition to Combat Colorectal Cancer.组合虚拟筛选揭示了一种用于抑制 Tankyrase 以对抗结直肠癌的新型骨架。
Biomedicines. 2022 Jan 10;10(1):143. doi: 10.3390/biomedicines10010143.
4
Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities.Wnt 信号通路在乳腺癌中的作用：生物学机制、挑战与机遇。
Mol Cancer. 2020 Nov 24;19(1):165. doi: 10.1186/s12943-020-01276-5.
5
The Modified Phenanthridine PJ34 Unveils an Exclusive Cell-Death Mechanism in Human Cancer Cells.改良菲啶PJ34揭示了人类癌细胞中一种独特的细胞死亡机制。
Cancers (Basel). 2020 Jun 19;12(6):1628. doi: 10.3390/cancers12061628.
6
From PARP1 to TNKS2 Inhibition: A Structure-Based Approach.从PARP1到TNKS2抑制：一种基于结构的方法。
ACS Med Chem Lett. 2020 Feb 3;11(5):862-868. doi: 10.1021/acsmedchemlett.9b00654. eCollection 2020 May 14.
7
The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts.菲衍生物PJ34能特异性消除异种移植模型中的人胰腺癌细胞。
Oncotarget. 2019 Oct 22;10(58):6269-6282. doi: 10.18632/oncotarget.27268.
8
A ribose-functionalized NAD with unexpected high activity and selectivity for protein poly-ADP-ribosylation.一种具有出乎意料的高活性和选择性的核糖基化 NAD，用于蛋白质多聚 ADP-核糖基化。
Nat Commun. 2019 Sep 13;10(1):4196. doi: 10.1038/s41467-019-12215-4.
9
Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.Tankyrase 依赖性聚（ADP-核糖）化和支架调节 Wnt/β-连环蛋白信号传导。
Br J Pharmacol. 2017 Dec;174(24):4611-4636. doi: 10.1111/bph.14038. Epub 2017 Nov 5.
10
Molecular regulation and pharmacological targeting of the β-catenin destruction complex.β-连环蛋白降解复合物的分子调控与药理学靶向。
Br J Pharmacol. 2017 Dec;174(24):4575-4588. doi: 10.1111/bph.13922. Epub 2017 Aug 11.
本文引用的文献
1
Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor.Tankyrase-2 与强效 Wnt 信号抑制剂相互作用的结构基础。
J Med Chem. 2010 Jul 22;53(14):5352-5. doi: 10.1021/jm100249w.
2
Features and development of Coot.Coot的特点与发展
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501. doi: 10.1107/S0907444910007493. Epub 2010 Mar 24.
3
XDS.XDS.（这个词如果没有更多背景信息，很难准确翻译出更有意义的内容，直接保留原文是一种处理方式，或者音译为“克斯达斯”之类，但感觉都不太符合常规翻译场景，你可以补充更多关于这个词的信息以便我更准确翻译 ）
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32. doi: 10.1107/S0907444909047337. Epub 2010 Jan 22.
4
Phaser crystallographic software.相位结晶学软件。
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674. doi: 10.1107/S0021889807021206. Epub 2007 Jul 13.
5
Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3.人聚（ADP - 核糖）聚合酶-3中抑制剂特异性的结构基础。
J Med Chem. 2009 May 14;52(9):3108-11. doi: 10.1021/jm900052j.
6
Zinc binding catalytic domain of human tankyrase 1.人端锚聚合酶1的锌结合催化结构域
J Mol Biol. 2008 May 23;379(1):136-45. doi: 10.1016/j.jmb.2008.03.058. Epub 2008 Apr 3.
7
Poly(ADP-ribose): novel functions for an old molecule.聚（ADP - 核糖）：一种古老分子的新功能。
Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28. doi: 10.1038/nrm1963.
8
9
Tankyrase promotes telomere elongation in human cells.端粒酶促进人类细胞中的端粒延长。
Curr Biol. 2000 Oct 19;10(20):1299-302. doi: 10.1016/s0960-9822(00)00752-1.
Zotero 插件